Isabel Gómez-Hurtado1,2, Paula Gimenez1,2, Irma García1, Pedro Zapater1,2,3, Rubén Francés1,2,4, José M González-Navajas1,2, Chaysavanh Manichanh1,5, José M Ramos6, Pablo Bellot1,2, Francisco Guarner1,5, José Such7,8. 1. CIBERehd, Instituto Salud Carlos III, Madrid, Spain. 2. Instituto Investigación Sanitaria y Biomédica Alicante (ISABIAL-FISABIO), Alicante, Spain. 3. Departamento Farmacología Clínica, UMH, Alicante, Spain. 4. Departamento Medicina Clínica, UMH, Alicante, Spain. 5. Departamento Gastroenterología, VHIR, Barcelona, Spain. 6. Departamento Medicina Interna, HGUA, Alicante, Spain. 7. Cleveland Clinic, Digestive Disease institute, Abu Dhabi, UAE. 8. Lerner School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Abstract
BACKGROUND & AIMS: Norfloxacin administration is useful in preventing bacterial infections in cirrhosis but associated to the generation of resistant species. Rifaximin is known to reach high concentrations in the intestinal lumen without generating relevant resistance in the intestinal flora. Our aim was to compare the effect of Norfloxacin and Rifaximin on intestinal flora composition, bacterial translocation and survival in cirrhotic rats. METHODS: Cirrhosis was induced in rats by oral administration of CCl4 . Animals were divided into three groups: only CCl4 (group I, n = 10); CCl4 + Norfloxacin (group II, n = 17) and CCl4 + Rifaximin (group III, n = 14). Gut bacterial composition, bacterial translocation and cytokine levels were measured. RESULTS: Forty-one rats were finally included. The incidence of viable and non-viable bacterial translocation was significantly reduced in animals receiving Norfloxacin; Rifaximin also decreased the incidence of viable and non-viable bacterial translocation, but did not reach statistical significance. Serum TNF-α levels were significantly lower in antibiotic groups. Norfloxacin modified intestinal microbiota, depleting significantly more pathobionts than Rifaximin. CONCLUSION: Norfloxacin is more effective than Rifaximin in preventing bacterial translocation in rats with cirrhosis probably because of its capacity to reduce pathobionts from intestinal microbiota.
BACKGROUND & AIMS:Norfloxacin administration is useful in preventing bacterial infections in cirrhosis but associated to the generation of resistant species. Rifaximin is known to reach high concentrations in the intestinal lumen without generating relevant resistance in the intestinal flora. Our aim was to compare the effect of Norfloxacin and Rifaximin on intestinal flora composition, bacterial translocation and survival in cirrhotic rats. METHODS:Cirrhosis was induced in rats by oral administration of CCl4 . Animals were divided into three groups: only CCl4 (group I, n = 10); CCl4 + Norfloxacin (group II, n = 17) and CCl4 + Rifaximin (group III, n = 14). Gut bacterial composition, bacterial translocation and cytokine levels were measured. RESULTS: Forty-one rats were finally included. The incidence of viable and non-viable bacterial translocation was significantly reduced in animals receiving Norfloxacin; Rifaximin also decreased the incidence of viable and non-viable bacterial translocation, but did not reach statistical significance. Serum TNF-α levels were significantly lower in antibiotic groups. Norfloxacin modified intestinal microbiota, depleting significantly more pathobionts than Rifaximin. CONCLUSION:Norfloxacin is more effective than Rifaximin in preventing bacterial translocation in rats with cirrhosis probably because of its capacity to reduce pathobionts from intestinal microbiota.
Authors: Yang Liu; Paul M Cavallaro; Byeong-Moo Kim; Tao Liu; Hongyan Wang; Florian Kühn; Fatemeh Adiliaghdam; Enyu Liu; Robin Vasan; Ehsan Samarbafzadeh; Matthew Z Farber; Junhui Li; Meng Xu; Vidisha Mohad; Michael Choi; Richard A Hodin Journal: Theranostics Date: 2021-01-01 Impact factor: 11.556
Authors: Paolo Caraceni; Victor Vargas; Elsa Solà; Carlo Alessandria; Koos de Wit; Jonel Trebicka; Paolo Angeli; Rajeshwar P Mookerjee; François Durand; Elisa Pose; Aleksander Krag; Jasmohan S Bajaj; Ulrich Beuers; Pere Ginès Journal: Hepatology Date: 2021-06-07 Impact factor: 17.425